High level MLL amplification in AML and MDS.

被引：0
|
作者：
Dolan, M [1 ]
Hirsch, B [1 ]
Eckfeldt, J [1 ]
机构：
[1] Univ Minnesota, Sch Med, Dept Lab Med & Pathol, Minneapolis, MN 55455 USA
来源：
AMERICAN JOURNAL OF CLINICAL PATHOLOGY | 2000年 / 114卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R36 [病理学];
学科分类号：
100104 ;
摘要：
55
引用
收藏
页码：315 / 315
页数：1
相关论文
共 50 条
  • [1] MLL amplification in MDS/AML
    Sambani, C.
    La Starza, R.
    Stavropoulou, C.
    Georgakakos, V.
    Manola, K.
    Rigana, H.
    Mecucci, C.
    CHROMOSOME RESEARCH, 2005, 13 : 194 - 194
  • [2] MLL gene amplification in MDS/AML
    Papenhausen, PR
    Tepperberg, JH
    Mowrey, PN
    Turk, K
    Gadi, IK
    AMERICAN JOURNAL OF HUMAN GENETICS, 1997, 61 (04) : A77 - A77
  • [3] The outcome of FUO during induction therapy of AML/MDS.
    Dabaja, B
    Kantarjian, H
    Pierce, S
    Keating, M
    Estey, E
    BLOOD, 1997, 90 (10) : 3761 - 3761
  • [4] The role of apoptosis, proliferation and amifostine in the myelodysplastic syndromes (MDS) and AML secondary to MDS.
    Parker, JE
    Fishlock, KL
    Pagliuca, A
    Mufti, GJ
    BLOOD, 1998, 92 (10) : 418A - 419A
  • [5] KARYOTYPE CLOSE TO TETRAPLOID IN AML AND MDS. A PURPOSE OF TWO CASES
    Francesca, Sartori
    Toral Fe, Serra
    Serra Antonia, Cladera
    Martinez Marta, Bernues
    Riera Martin, Mascaro
    Maria Antonia, Duran
    HAEMATOLOGICA, 2016, 101 : 322 - 322
  • [6] Pneumonia during remission induction chemotherapy in patients with AML or MDS.
    Wilhelm, M
    Kantarjian, HM
    OBrien, S
    Pierce, S
    Keating, MJ
    Freireich, EJ
    Estey, EH
    BLOOD, 1996, 88 (10) : 3411 - 3411
  • [7] Secondary AML with MLL gene amplification
    Xu, Ke
    Nacheva, Elisabeth
    BLOOD, 2022, 140 (02) : 161 - 161
  • [8] A patient-reported outcome measure for symptoms of AML/MDS.
    Williams, Loretta A.
    Garcia-Gonzalez, Araceli
    Ahaneku, Hycienth
    Cortes, Jorge E.
    Garcia-Manero, Guillermo
    Kantarjian, Hagop M.
    Shi, Qiuling
    Borthakur, Gautam
    Burger, Jan Andreas
    Jabbour, Elias
    Takahashi, Koichi
    Lin, Huei-Kai
    Limaye, Achala
    Cleeland, Charles S.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [9] The influence of cytogenetic abnormalities on treatment outcome after intensive antileukemic therapy for patients with high risk MDS and AML following MDS.
    DeWitte
    Suciu, S
    Boogaerts, M
    Labar, B
    Archimbaud, E
    Aul, C
    Selleslag, D
    Ferrant, A
    Weijermans, P
    Mandelli, F
    Amadori, S
    Jehn, U
    Muus, P
    DeMuynck, H
    Dardenne, M
    Willemze, R
    Gratwohl, A
    Apperley, J
    BLOOD, 1996, 88 (10) : 1806 - 1806
  • [10] Role of fludarabine containing regimens in newly-diagnosed AML or MDS.
    Estey, E
    Thall, P
    Kantarjian, H
    Pierce, S
    Freireich, E
    BLOOD, 1998, 92 (10) : 232A - 233A
12345